Glenmark Re-Evaluates Complex Generics Basket, Won’t Be Part Of The 'Crowd'

Glenmark has ended development of certain in-licensed complex generic assets including generic versions of Abraxane and Suboxone in view of the extremely competitive landscape in the US. The Indian firm says it would rather focus on products where it is an early entrant.

Pros & Cons
GLENMARK HAS DISCONTINUED DEVELOPMENT OF CERTAIN COMPLEX GENERICS

Competitive pressure in the US market is forcing some Indian companies to rethink their product portfolios including in the complex generics space, once considered a relatively safe haven in terms of both number of participants vying for a share of the pie and intensity of price erosion.

Glenmark Pharmaceuticals Ltd. said it was no longer pursuing development of four in-licensed complex generic assets as the “overall...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from India

More from Focus On Asia